Characterization of anti-MERS-CoV antibodies against various recombinant structural antigens of MERS-CoV in an imported case in China.
Identifieur interne : 001195 ( PubMed/Checkpoint ); précédent : 001194; suivant : 001196Characterization of anti-MERS-CoV antibodies against various recombinant structural antigens of MERS-CoV in an imported case in China.
Auteurs : Wenling Wang [République populaire de Chine] ; Huijuan Wang [République populaire de Chine] ; Yao Deng [République populaire de Chine] ; Tie Song [République populaire de Chine] ; Jiaming Lan [République populaire de Chine] ; Guizhen Wu [République populaire de Chine] ; Changwen Ke [République populaire de Chine] ; Wenjie Tan [République populaire de Chine]Source :
- Emerging microbes & infections [ 2222-1751 ] ; 2016.
Descripteurs français
- KwdFr :
- Anticorps antiviraux (immunologie), Anticorps antiviraux (sang), Anticorps neutralisants (sang), Antigènes viraux (immunologie), Chine, Coronavirus du syndrome respiratoire du Moyen-Orient (), Coronavirus du syndrome respiratoire du Moyen-Orient (immunologie), Glycoprotéine de spicule des coronavirus (immunologie), Humains, Immunoglobuline G (sang), Immunoglobuline M (sang), Infections à coronavirus (immunologie), Infections à coronavirus (virologie), Mâle, Nucléoprotéines (immunologie), Protéines recombinantes (immunologie), Test ELISA, Tests de neutralisation.
- MESH :
- immunologie : Anticorps antiviraux, Antigènes viraux, Coronavirus du syndrome respiratoire du Moyen-Orient, Glycoprotéine de spicule des coronavirus, Infections à coronavirus, Nucléoprotéines, Protéines recombinantes.
- sang : Anticorps antiviraux, Anticorps neutralisants, Immunoglobuline G, Immunoglobuline M.
- virologie : Infections à coronavirus.
- Chine, Coronavirus du syndrome respiratoire du Moyen-Orient, Humains, Mâle, Test ELISA, Tests de neutralisation.
English descriptors
- KwdEn :
- Antibodies, Neutralizing (blood), Antibodies, Viral (blood), Antibodies, Viral (immunology), Antigens, Viral (immunology), China, Coronavirus Infections (immunology), Coronavirus Infections (virology), Enzyme-Linked Immunosorbent Assay, Humans, Immunoglobulin G (blood), Immunoglobulin M (blood), Male, Middle East Respiratory Syndrome Coronavirus (chemistry), Middle East Respiratory Syndrome Coronavirus (immunology), Neutralization Tests, Nucleoproteins (immunology), Recombinant Proteins (immunology), Spike Glycoprotein, Coronavirus (immunology).
- MESH :
- chemical , blood : Antibodies, Neutralizing, Antibodies, Viral, Immunoglobulin G, Immunoglobulin M.
- chemical , immunology : Antibodies, Viral, Antigens, Viral, Nucleoproteins, Recombinant Proteins, Spike Glycoprotein, Coronavirus.
- chemistry : Middle East Respiratory Syndrome Coronavirus.
- immunology : Coronavirus Infections, Middle East Respiratory Syndrome Coronavirus.
- virology : Coronavirus Infections.
- China, Enzyme-Linked Immunosorbent Assay, Humans, Male, Neutralization Tests.
Abstract
The first imported case of Middle East respiratory syndrome (MERS) in China recently occurred, allowing for the characterization of antibody titers in a series of the patient's sera using the following methods based on recombinant viral structural antigens: inactivated MERS coronavirus (MERS-CoV) enzyme-linked immunosorbent assay (ELISA), recombinant MERS-CoV spike (S, or fragments of S) ELISA, nucleoprotein (NP) ELISA and MERS S pseudovirus particle-based neutralization test (ppNT). A longitudinal profile of the infection showed that seroconversion detected by ELISAs based on the recombinant extracellular domain, S, S1 and receptor-binding domain (RBD) antigens occurred as early as neutralizing antibodies were detected by the ppNT and earlier than antibodies were detected by the inactivated MERS-CoV and N-terminal domain (NTD) ELISAs. Antibodies detected by the NP ELISA occurred last. Strong correlations were found between the S1, RBD and NP ELISAs and the inactivated MERS-CoV ELISA. The S and RBD ELISAs were highly correlated with the commercial S1 ELISA. The S ELISA strongly correlated with the ppNT, although the MERS-CoV, S1, NTD and RBD ELISAs were also significantly correlated with the ppNT (P<0.001).
DOI: 10.1038/emi.2016.114
PubMed: 27826140
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:27826140Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Characterization of anti-MERS-CoV antibodies against various recombinant structural antigens of MERS-CoV in an imported case in China.</title>
<author><name sortKey="Wang, Wenling" sort="Wang, Wenling" uniqKey="Wang W" first="Wenling" last="Wang">Wenling Wang</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wang, Huijuan" sort="Wang, Huijuan" uniqKey="Wang H" first="Huijuan" last="Wang">Huijuan Wang</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Deng, Yao" sort="Deng, Yao" uniqKey="Deng Y" first="Yao" last="Deng">Yao Deng</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Song, Tie" sort="Song, Tie" uniqKey="Song T" first="Tie" last="Song">Tie Song</name>
<affiliation wicri:level="1"><nlm:affiliation>Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, Guangdong Province, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, Guangdong Province</wicri:regionArea>
<wicri:noRegion>Guangdong Province</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lan, Jiaming" sort="Lan, Jiaming" uniqKey="Lan J" first="Jiaming" last="Lan">Jiaming Lan</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wu, Guizhen" sort="Wu, Guizhen" uniqKey="Wu G" first="Guizhen" last="Wu">Guizhen Wu</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ke, Changwen" sort="Ke, Changwen" uniqKey="Ke C" first="Changwen" last="Ke">Changwen Ke</name>
<affiliation wicri:level="1"><nlm:affiliation>Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, Guangdong Province, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, Guangdong Province</wicri:regionArea>
<wicri:noRegion>Guangdong Province</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tan, Wenjie" sort="Tan, Wenjie" uniqKey="Tan W" first="Wenjie" last="Tan">Wenjie Tan</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27826140</idno>
<idno type="pmid">27826140</idno>
<idno type="doi">10.1038/emi.2016.114</idno>
<idno type="wicri:Area/PubMed/Corpus">000F00</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F00</idno>
<idno type="wicri:Area/PubMed/Curation">000F00</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000F00</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001195</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001195</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Characterization of anti-MERS-CoV antibodies against various recombinant structural antigens of MERS-CoV in an imported case in China.</title>
<author><name sortKey="Wang, Wenling" sort="Wang, Wenling" uniqKey="Wang W" first="Wenling" last="Wang">Wenling Wang</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wang, Huijuan" sort="Wang, Huijuan" uniqKey="Wang H" first="Huijuan" last="Wang">Huijuan Wang</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Deng, Yao" sort="Deng, Yao" uniqKey="Deng Y" first="Yao" last="Deng">Yao Deng</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Song, Tie" sort="Song, Tie" uniqKey="Song T" first="Tie" last="Song">Tie Song</name>
<affiliation wicri:level="1"><nlm:affiliation>Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, Guangdong Province, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, Guangdong Province</wicri:regionArea>
<wicri:noRegion>Guangdong Province</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lan, Jiaming" sort="Lan, Jiaming" uniqKey="Lan J" first="Jiaming" last="Lan">Jiaming Lan</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wu, Guizhen" sort="Wu, Guizhen" uniqKey="Wu G" first="Guizhen" last="Wu">Guizhen Wu</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ke, Changwen" sort="Ke, Changwen" uniqKey="Ke C" first="Changwen" last="Ke">Changwen Ke</name>
<affiliation wicri:level="1"><nlm:affiliation>Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, Guangdong Province, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, Guangdong Province</wicri:regionArea>
<wicri:noRegion>Guangdong Province</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tan, Wenjie" sort="Tan, Wenjie" uniqKey="Tan W" first="Wenjie" last="Tan">Wenjie Tan</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Emerging microbes & infections</title>
<idno type="eISSN">2222-1751</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Neutralizing (blood)</term>
<term>Antibodies, Viral (blood)</term>
<term>Antibodies, Viral (immunology)</term>
<term>Antigens, Viral (immunology)</term>
<term>China</term>
<term>Coronavirus Infections (immunology)</term>
<term>Coronavirus Infections (virology)</term>
<term>Enzyme-Linked Immunosorbent Assay</term>
<term>Humans</term>
<term>Immunoglobulin G (blood)</term>
<term>Immunoglobulin M (blood)</term>
<term>Male</term>
<term>Middle East Respiratory Syndrome Coronavirus (chemistry)</term>
<term>Middle East Respiratory Syndrome Coronavirus (immunology)</term>
<term>Neutralization Tests</term>
<term>Nucleoproteins (immunology)</term>
<term>Recombinant Proteins (immunology)</term>
<term>Spike Glycoprotein, Coronavirus (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps antiviraux (immunologie)</term>
<term>Anticorps antiviraux (sang)</term>
<term>Anticorps neutralisants (sang)</term>
<term>Antigènes viraux (immunologie)</term>
<term>Chine</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient ()</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient (immunologie)</term>
<term>Glycoprotéine de spicule des coronavirus (immunologie)</term>
<term>Humains</term>
<term>Immunoglobuline G (sang)</term>
<term>Immunoglobuline M (sang)</term>
<term>Infections à coronavirus (immunologie)</term>
<term>Infections à coronavirus (virologie)</term>
<term>Mâle</term>
<term>Nucléoprotéines (immunologie)</term>
<term>Protéines recombinantes (immunologie)</term>
<term>Test ELISA</term>
<term>Tests de neutralisation</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Neutralizing</term>
<term>Antibodies, Viral</term>
<term>Immunoglobulin G</term>
<term>Immunoglobulin M</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term>
<term>Antigens, Viral</term>
<term>Nucleoproteins</term>
<term>Recombinant Proteins</term>
<term>Spike Glycoprotein, Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Antigènes viraux</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Infections à coronavirus</term>
<term>Nucléoprotéines</term>
<term>Protéines recombinantes</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Middle East Respiratory Syndrome Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Anticorps neutralisants</term>
<term>Immunoglobuline G</term>
<term>Immunoglobuline M</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>China</term>
<term>Enzyme-Linked Immunosorbent Assay</term>
<term>Humans</term>
<term>Male</term>
<term>Neutralization Tests</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Chine</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Humains</term>
<term>Mâle</term>
<term>Test ELISA</term>
<term>Tests de neutralisation</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The first imported case of Middle East respiratory syndrome (MERS) in China recently occurred, allowing for the characterization of antibody titers in a series of the patient's sera using the following methods based on recombinant viral structural antigens: inactivated MERS coronavirus (MERS-CoV) enzyme-linked immunosorbent assay (ELISA), recombinant MERS-CoV spike (S, or fragments of S) ELISA, nucleoprotein (NP) ELISA and MERS S pseudovirus particle-based neutralization test (ppNT). A longitudinal profile of the infection showed that seroconversion detected by ELISAs based on the recombinant extracellular domain, S, S1 and receptor-binding domain (RBD) antigens occurred as early as neutralizing antibodies were detected by the ppNT and earlier than antibodies were detected by the inactivated MERS-CoV and N-terminal domain (NTD) ELISAs. Antibodies detected by the NP ELISA occurred last. Strong correlations were found between the S1, RBD and NP ELISAs and the inactivated MERS-CoV ELISA. The S and RBD ELISAs were highly correlated with the commercial S1 ELISA. The S ELISA strongly correlated with the ppNT, although the MERS-CoV, S1, NTD and RBD ELISAs were also significantly correlated with the ppNT (P<0.001).</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27826140</PMID>
<DateCompleted><Year>2017</Year>
<Month>01</Month>
<Day>31</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2222-1751</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>5</Volume>
<Issue>11</Issue>
<PubDate><Year>2016</Year>
<Month>Nov</Month>
<Day>09</Day>
</PubDate>
</JournalIssue>
<Title>Emerging microbes & infections</Title>
<ISOAbbreviation>Emerg Microbes Infect</ISOAbbreviation>
</Journal>
<ArticleTitle>Characterization of anti-MERS-CoV antibodies against various recombinant structural antigens of MERS-CoV in an imported case in China.</ArticleTitle>
<Pagination><MedlinePgn>e113</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/emi.2016.114</ELocationID>
<Abstract><AbstractText>The first imported case of Middle East respiratory syndrome (MERS) in China recently occurred, allowing for the characterization of antibody titers in a series of the patient's sera using the following methods based on recombinant viral structural antigens: inactivated MERS coronavirus (MERS-CoV) enzyme-linked immunosorbent assay (ELISA), recombinant MERS-CoV spike (S, or fragments of S) ELISA, nucleoprotein (NP) ELISA and MERS S pseudovirus particle-based neutralization test (ppNT). A longitudinal profile of the infection showed that seroconversion detected by ELISAs based on the recombinant extracellular domain, S, S1 and receptor-binding domain (RBD) antigens occurred as early as neutralizing antibodies were detected by the ppNT and earlier than antibodies were detected by the inactivated MERS-CoV and N-terminal domain (NTD) ELISAs. Antibodies detected by the NP ELISA occurred last. Strong correlations were found between the S1, RBD and NP ELISAs and the inactivated MERS-CoV ELISA. The S and RBD ELISAs were highly correlated with the commercial S1 ELISA. The S ELISA strongly correlated with the ppNT, although the MERS-CoV, S1, NTD and RBD ELISAs were also significantly correlated with the ppNT (P<0.001).</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Wenling</ForeName>
<Initials>W</Initials>
<AffiliationInfo><Affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Huijuan</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Deng</LastName>
<ForeName>Yao</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Song</LastName>
<ForeName>Tie</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, Guangdong Province, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lan</LastName>
<ForeName>Jiaming</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wu</LastName>
<ForeName>Guizhen</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ke</LastName>
<ForeName>Changwen</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, Guangdong Province, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tan</LastName>
<ForeName>Wenjie</ForeName>
<Initials>W</Initials>
<AffiliationInfo><Affiliation>Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2016</Year>
<Month>11</Month>
<Day>09</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Emerg Microbes Infect</MedlineTA>
<NlmUniqueID>101594885</NlmUniqueID>
<ISSNLinking>2222-1751</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007075">Immunoglobulin M</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009698">Nucleoproteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N">China</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007075" MajorTopicYN="N">Immunoglobulin M</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009698" MajorTopicYN="N">Nucleoproteins</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year>
<Month>06</Month>
<Day>14</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2016</Year>
<Month>08</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2016</Year>
<Month>09</Month>
<Day>04</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>11</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>11</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>2</Month>
<Day>1</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27826140</ArticleId>
<ArticleId IdType="pii">emi2016114</ArticleId>
<ArticleId IdType="doi">10.1038/emi.2016.114</ArticleId>
<ArticleId IdType="pmc">PMC5148018</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Clin Diagn Lab Immunol. 2004 Jul;11(4):665-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15242938</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Vaccine Immunol. 2007 Jul;14(7):839-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17475765</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Microbes Infect. 2015 Dec 02;4(12 ):e74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26632876</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EBioMedicine. 2015 Aug 18;2(10):1438-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26629538</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 Jul 31;349(5):508-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12890855</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2013 Aug 8;500(7461):227-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23831647</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Rep. 2016 May 05;6:25359</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27146253</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2014 Aug 28;371(9):828-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25162889</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2016 Feb 15;62(4):477-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26565003</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2015 Dec;21(12 ):2186-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26583829</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2015 Jun 18;20(24):null</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26111235</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2015 ;20(41):null</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26538277</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2015 Dec;21(12):2278-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26583433</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>République populaire de Chine</li>
</country>
<settlement><li>Pékin</li>
</settlement>
</list>
<tree><country name="République populaire de Chine"><noRegion><name sortKey="Wang, Wenling" sort="Wang, Wenling" uniqKey="Wang W" first="Wenling" last="Wang">Wenling Wang</name>
</noRegion>
<name sortKey="Deng, Yao" sort="Deng, Yao" uniqKey="Deng Y" first="Yao" last="Deng">Yao Deng</name>
<name sortKey="Ke, Changwen" sort="Ke, Changwen" uniqKey="Ke C" first="Changwen" last="Ke">Changwen Ke</name>
<name sortKey="Lan, Jiaming" sort="Lan, Jiaming" uniqKey="Lan J" first="Jiaming" last="Lan">Jiaming Lan</name>
<name sortKey="Song, Tie" sort="Song, Tie" uniqKey="Song T" first="Tie" last="Song">Tie Song</name>
<name sortKey="Tan, Wenjie" sort="Tan, Wenjie" uniqKey="Tan W" first="Wenjie" last="Tan">Wenjie Tan</name>
<name sortKey="Wang, Huijuan" sort="Wang, Huijuan" uniqKey="Wang H" first="Huijuan" last="Wang">Huijuan Wang</name>
<name sortKey="Wu, Guizhen" sort="Wu, Guizhen" uniqKey="Wu G" first="Guizhen" last="Wu">Guizhen Wu</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001195 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001195 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= MersV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:27826140 |texte= Characterization of anti-MERS-CoV antibodies against various recombinant structural antigens of MERS-CoV in an imported case in China. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:27826140" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a MersV1
This area was generated with Dilib version V0.6.33. |